Deutsche Bank Said FDA Guidance Documents Support Dendreon's (DNDN) Provenge Approval
Tweet Send to a Friend
Deutsche Bank is making some comments on Dendreon Corp. (Nasdaq: DNDN) this morning, maintaining thier Buy rating and $36 price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
